A study published in collaboration with the University of Cologne evaluated the effects of intravitreal injections of CPV-104 on ocular disease processes. Image credit: ©jitendra jadhav – stock.adobe.com
Eleva has published new data on its lead pipeline asset CPV-104, a recombitant variant of human complement factor H. These data will appear in the Journal of Neuroinflammation, a peer-reviewed, open access journal focused on the interactions of the immune system.
In an established animal model of age-related macular degeneration (AMD), Eleva’s recombinant human CPV-104 improved two hallmarks of the disease by statistically significantly dampening the inflammatory activity of microglia and Müller cells in the eye and attenuating light-induced retinal degeneration, the company said in a press release.